Logo

Biocrates To Provide Metabolomics Services for EU Cancer Biomarker Study

May 10, 2007
NEW YORK (GenomeWeb News) - Biocrates Life Sciences has joined a European Union project to find diagnostic biomarkers for colon and breast cancer, the company said today.
 
Biocrates, based in Innsbruck, Austria, said that it will perform metabolomics services for the study, called COBRED for Colon and Breast cancer Diagnostics.
 
The company said it will use its TargetIDQ metabolomics platform to identify and quantify more than 1,000 metabolites in the study.
 
The study is funded by the EU’s Sixth Framework program and involves eight partners from France, Hungary, Estonia, and Austria. The goal of the study is to discover biomarkers to assess the risk of cancer recurrence after initial tumor removal.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.